The end of the covid pandemic is not yet in sight, despite increased immunity of the population through vaccination or previous infection. Knowledge about the treatment of COVID-19 has increased, and dexamethasone and are now part of the standard treatment in hospitalized patients with severe COVID-19.
Baricitinib
Baricitinib, a janus kinase inhibitor that has been registered for, among other things, rheumatoid arthritis, is now also used in the treatment of seriously ill Covid patients. Research shows that this drug is moderately effective in these patients. Does baricitinib already deserve a permanent place in the treatment of seriously ill covid patients?
Ge-Bu Location
What is the Ge-Bu’s position?
• A meta-analysis shows that adding the janus kinase inhibitor baricitinib to standard treatment for COVID-19 significantly reduces mortality at 28 days compared to placebo with a number needed to treat (NNT) of 49.
• Baricitinib is not yet included in the Dutch Covid guideline of the Antibiotic Policy Working Group (SWAB) foundation, but it is in the guidelines in the United States and the United Kingdom.
• Baricitinib can be used in severely ill covid patients, but further research should show which combination of covid agents baricitinib is most effective for.
Read the full article